Teva Pharmaceutical Industries Ltd (TEVA)
10.71
-0.05 (-0.46%)
USD |
NYSE |
Feb 06, 11:07
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 11.90B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 25.55% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.7848 |
| Price to Book Value | 1.357 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 2.426 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 90.81% |
News
Headline
Wire
Time (ET)
MT Newswires
01/30 10:43
Yahoo
01/25 10:53
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 02/08/2023 | 08:00 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 02/08/2023 | -- | Results | Q4 2022 | -- | 0.71 | -- | |
| 11/03/2022 | -- | Results | Q3 2022 | 0.59 | 0.62 | -4.22% | |
| 11/03/2022 | 08:00 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 07/27/2022 | -- | Results | Q2 2022 | 0.68 | 0.56 | 20.57% | |
| 07/27/2022 | 08:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 05/03/2022 | 08:00 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 05/03/2022 | -- | Results | Q1 2022 | 0.55 | 0.55 | 0.18% |
*Estimated Date/Time
Earnings
Profile
Edit
| Based in Israel, Teva is one of the world’s largest generic drug manufacturers, with over 3,500 products marketed in over 60 countries. While a majority of its revenue is attributed to prescription generic drugs, Teva develops and markets its own branded specialty and biopharmaceutical products, primarily in the U.S. and in Europe. The company’s branded portfolio generates one fifth of total revenue and consists of patented therapies targeting central nervous system conditions (Austedo, Ajovy, Copaxone), oncology (Bendeka/Treanda), and respiratory conditions (ProAir, Qvar). While global competition has facilitated the commodification of small-molecule generic drugs, Teva’s portfolio rationalization has resulted in less overall price erosion versus peers. |
| URL | https://www.tevapharm.com |
| Investor Relations URL | https://ir.tevapharm.com/ |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Equity Style | Mid Cap/Value |
| Next Earnings Release | Feb. 08, 2023 |
| Last Earnings Release | Nov. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Nov. 27, 2017 |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | 0.00 |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | Quarterly |
| Last Ex-Dividend Date | Nov. 27, 2017 |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of February 03, 2023.
Fundamentals
| Revenue (TTM) | 15.14B |
| Total Expenses (TTM) | 12.28B |
| Net Income (TTM) | -1.29B |
| Total Assets (Quarterly) | 44.25B |
| Total Liabilities (Quarterly) | 34.73B |
| Shareholders Equity (Quarterly) | 8.767B |
| Cash from Operations (TTM) | 1.073B |
| Cash from Investing (TTM) | 734.00M |
| Cash from Financing (TTM) | -1.277B |
Ratings
Profile
Edit
| Based in Israel, Teva is one of the world’s largest generic drug manufacturers, with over 3,500 products marketed in over 60 countries. While a majority of its revenue is attributed to prescription generic drugs, Teva develops and markets its own branded specialty and biopharmaceutical products, primarily in the U.S. and in Europe. The company’s branded portfolio generates one fifth of total revenue and consists of patented therapies targeting central nervous system conditions (Austedo, Ajovy, Copaxone), oncology (Bendeka/Treanda), and respiratory conditions (ProAir, Qvar). While global competition has facilitated the commodification of small-molecule generic drugs, Teva’s portfolio rationalization has resulted in less overall price erosion versus peers. |
| URL | https://www.tevapharm.com |
| Investor Relations URL | https://ir.tevapharm.com/ |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Equity Style | Mid Cap/Value |
| Next Earnings Release | Feb. 08, 2023 |
| Last Earnings Release | Nov. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Nov. 27, 2017 |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| TEVA Tweets |